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Abstract
Purpose Phosphodiesterase type-5 inhibitor administration
in diabetic men with erectile dysfunction (ED) is associated
with reduced waist circumference. We evaluated potential
effects of daily tadalafil administration on body composition
and investigated its possible mechanism(s) of action in
C2C12 skeletal muscle cells in vitro.
Methods Forty-three men on stable caloric intake (mean
age 48.5± 7; BMI 25.5± 0.9 kg/m2) complaining mild ED
and/or low urinary tract symptoms (LUTS) were randomly
assigned to receive tadalafil (TAD) 5 mg/daily (once-a-
day=OAD-TAD; n= 23) or 20 mg on-demand (on-demand=
OD-TAD; n= 20) for 2 months. Primary outcomes were
variations of body composition measured by Dual-energy
X-ray absorptiometry; secondary outcomes were ED/LUTS
questionnaire scores along with hormone (testosterone,
estradiol, insulin) and endothelial function (Endopat2000)
variations.
Results OAD-TAD increased abdominal lean mass (p<
0.01) that returned to baseline after 2 months withdrawal.
LUTS scores improved (p<0.01) in OD-TAD while ED
scores improved (p< 0.01) in both groups. We found
significant improvements in endothelial function (p< 0.05)
that directly correlated with serum insulin (p< 0.01;
r= 0.3641) and inversely correlated with estradiol levels
(p< 0.01; r= 0.3655) even when corrected for potential
confounders. Exposure of C2C12 cells upon increasing
tadalafil concentrations (10−7 to 10−6 M) increased total
androgen receptor mRNA and protein expression as
well as myogenin protein expression after 24 and 72 h
(2.8 ± 0.4-fold and 1.4± 0.02-fold vs. control, respectively,
p< 0.05).
Conclusions Daily tadalafil improved lean mass content in
non-obese men probably via enhanced insulin secretion, estra-
diol reduction, and improvement of endothelial function in vivo.
The in vitro increased myogenin and androgen receptor protein
expression in skeletal muscle cells suggests a translational action
of phosphodiesterase type-5 on this receptor.
Keywords Testosterone ● Estradiol ● Phosphodiesterase
type-5 ● Erectile Dysfunction ● Androgen receptor ● Skeletal
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Introduction
Phosphodiesterases (PDEs) are a family of enzymes with
different selectivity for cyclic nucleotides, cAMP, and
cGMP, [1] that play several regulatory roles such as platelet
aggregation, T-cell activation, and smooth cell relaxation
and vascular tone [2, 3]. In addition, the NO-cGMP sig-
naling pathway seems to play an important role in the
regulation of muscle metabolism [4] and insulin action [5].
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PDE5 inhibitors (PDE5i) are selective blockers of the
cGMP-hydrolyzing enzyme. In men with erectile dysfunc-
tion (ED) chronic PDE5i improves insulin secretion, [6]
endothelial function, [7] and in vitro it regulates aromatase
(ARO) expression both in adipocyte [8] and osteoblast cell
models. [9] Interestingly, data from experimental rabbit
model of high fat diet-induced metabolic syndrome (MetS)
confirms that tadalafil (TAD) administration not only after
long-term (12 weeks), but even after a short-term exposure
(1 week), in vivo and in vitro, was able to restore a correct
pre-adipocyte commitment, through a positive effect on
insulin sensitivity, and to upregulate, via PKG activation,
the genes related to mitochondrial biogenesis and brown
adipogenesis, including UCP1 [10]. Studies in men with
type-2 diabetes (T2D) confirmed that chronic sildenafil
administration was able to reduce epicardial adipose tissue
and in a murine diabetic model regulated visceral adiposity
by shifting adipose tissue cell composition toward a less
inflamed profile [11]. No data on possible effects of PDE5
inhibitors on lean mass in humans have been described yet.
We aimed to investigate the potential effects of daily
TAD treatment on lean mass, hormonal, and endothelial
function in men with mild ED and/or LUTS. We addi-
tionally used C2C12 skeletal muscle cell line to evaluate the
in vitro effect of TAD during myogenic differentiation by




This was an open label, parallel arm design study aimed to
determine the potential effects of TAD assumption on body
composition. Forty three male subjects (≥18 years–BMI ≥
18.5 ≤ 25 kg/mg2) affected by mild ED and/or LUTS were
enrolled. They were randomly allocated to receive either
TAD 5mg/daily (OAD-TAD; n= 23) or TAD 20mg on-
demand (OD-TAD; n= 20) for 2 months. Three scheduled
visits were planned: baseline, 2-months after each respective
treatment, and 2 months follow-up, with following evalua-
tions: general physical examination, anthropometric para-
meters [body weight (BW), height, BMI, and waist
circumference (WC)]; body composition [fat mass (FM), lean
mass (FFM)], endothelial function, fasting serum sample,
International Index of Erectile Function-5 items (IIEF-5), and
International Prostate Symptom Score (IPSS) questionnaires.
Primary outcomes were variations from baseline of body
composition; secondary outcomes were variations from
baseline of the IIEF-5, IPSS, total testosterone (TT), 17β-
estradiol (E), T/E ratios, fasting insulin levels, endothelial
function (TBo). The clinical study was carried out in an in-
office setting at Sapienza University of Rome and each
patient signed a detailed informed consent (Study ID 2369,
committee approval #166/12); ClinicalTrials.gov
(NCT02554045). To clarify the potential cellular and
molecular mechanisms on body composition, in vitro
experiments were performed to further highlight intracel-
lular events triggered by TAD exposure in skeletal muscle
cells. Thus, C2C12 cell line was used to investigate the
effects of TAD on myogenic differentiation. Given that
testosterone (T)-androgen receptor (AR) signaling pathway
plays an important role in early myogenesis [12, 13] by
increasing AR expression during C2C12 differentiation [14]
and that TAD increases AR expression and T release in
human osteoblasts, we evaluated effects on AR expression
during early stages of muscle cells differentiation.
Exclusion criteria
IIEF5< 17 (patients with severe ED), IPSS> 7 (patients with
severe LUTS), any concomitant treatment during the prior
3 months, lifestyle, diet or physical exercise changes attended
within the 16 weeks of study duration; patients potentially
trying to become father; significant hepatic, respiratory,
hematological or renal disease; history of drugs or alcohol
abuse; history or presence of any cancer; any other reason
that the investigator feels precludes patients safety.
Dual-energy X-ray absorptiometry (DEXA) assessment
Body composition was evaluated by DEXA (DEXA-
Hologic QDR-1000), according to previously published
procedures [15]. We modified calculations for android
abdominal section, by using the area included between the
line joining the last inferior ribs and the line joining the
superior iliac spines. Long-term precision error was 0.54%
(phantom); short-term precision error was 1.2% for the
lumbar spine and 2% for the femoral neck. Fat Free Mass
(FFM) and Fat Mass (FM) was expressed in grams per
square centimeter (g). DEXA soft tissue measurements
variation coefficient was FFM: 1.067% and FM: 1.748%.
Endothelial function
Endothelial function was investigated by peripheral arterial
tonometry (PAT; EndoPAT2000, Itamar Medical), accord-
ing to previously published procedures [16]. Instead of the
natural logarithm of PAT ratio, we evaluated the average
amplitude of PAT signal in the post-occlusion period (test
signal, T) compared with that in the baseline (B) signal
before occlusion, utilizing the same time intervals as for
reactive hyperemia index (RHI) calculation, but not indexed




TT and E were measured by chemiluminescence micro-
particle immunoassay (CMIA, Architect System, Abbott
Laboratories, IL, USA), with a detection limit of 0.28 nmol/L
and 10 pg/mL, respectively (intra-assay and interassay coef-
ficients of variation for TT: 2.1 and 3.6% at 10.08 nmol/L),
with reference values 2.8–11 ng/mL (T) and 25–107 pg/mL
(E2). Insulin levels were analyzed by immunometric assay
based on chemiluminescence using an automated clinical
chemistry analyzer (Immulite 2000, Diagnostic Product
Corp., Los Angeles, CA, USA) [18].
Cell culture and treatments
C2C12 skeletal muscle cells (CRL-1772; American Type
Culture Collection, Manassas, VA, USA) were cultured in
Dulbecco’s modified Eagle medium without phenol red
(DMEM; Euroclone, Milan, Italy) supplemented with 10%
heat-inactivated fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) and 1% penicillin and streptomycin (Sigma-
Aldrich, St. Louis, MO, USA) under an atmosphere of 5%
CO2 in humidified air at 37 °C. In all experiments, cells
were seeded at the density of 104 cells/cm2 and allowed to
grow until 80% confluence. To induce myogenic differ-
entiation, fetal bovine serum content was lowered to 2%.
TAD (kindly supplied by ELI Lilly ICOS Corporation) was
added after the induction of myogenic differentiation. Cells
were harvested for molecular analysis after 12, 24, 48, and
72 h of differentiation.
Protein extraction and immunoblot analysis
Following treatments, cells were washed with PBS and
lysed in fresh ice-cold RIPA buffer (Sigma-Aldrich) sup-
plemented before use with protease and phosphatase inhi-
bitor cocktails (Roche, Indianapolis, IN, USA). Lysates
were precleared by centrifugation and protein content was
measured using Pierce® BCA protein assay kit (Thermo
Fisher Scientific, Waltham, MA, USA). Samples were
boiled for 5 min; then an equal amount of protein extracts
(15–30 µg) was resolved in SDS-polyacrylamide gels
(10–14%) and transferred to polyvinylidene difluoride
(PVDF) membranes (Amersham Biosciences, Piscataway,
NJ, USA). Membranes were saturated by incubation at
room temperature for 1 h with 5% (w/v) non-fat dry milk in
20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween 20, and
incubated with specific first antibodies (1:1000) overnight at
4 °C. Antibodies against class I myosin (MyoD), Myogenin,
and myosin heavy chain (MyHC) (H300) were from Santa
Cruz Biotechnology (Dallas, Texas, USA); AR, CYP19,
and β-actin antibodies from Cell Signaling Technology
(Danvers, MA, USA); β-actin and GAPDH antibodies from
Sigma-Aldrich. Immunoreactive protein bands were detec-
ted by incubation for 1 h with horseradish peroxidase-
conjugated secondary goat anti-rabbit (1:10000, Merck
Millipore, Billeric, MA, USA) or goat anti-mouse (1:10000,
Sigma-Aldrich) in blocking solution at room temperature,
visualized by enhanced chemiluminescence (Amersham
Biosciences), then bands were obtained on the ImageQuant
LAS 4000 (GEHC).
Immunofluorescence and myogenic differentiation
assays
Cells were washed twice with cold PBS, fixed with 4% for-
maldehyde, permeabilized with 0.2% Triton X-100 in PBS
and fixed in blocking solution (6 ng/ml IgG from goat serum
in PBS) for 30 min. Cells were incubated with anti-MyHC
antibody (1:300, Santa Cruz Biotechnology) overnight at
4 °C. Alexa Fluor 488-conjugated anti-rabbit IgG (H + L) was
used as secondary antibody (1:500, Thermo Fisher Scientific).
After counterstaining with 4′,6-Diamidino-2-phenylindole
dihydrochloride (DAPI; 500 ng/ml), slides were mounted
with Prolong Gold Antifade Reagent (Invitrogen).
Myogenic differentiation was evaluated by calculating
differentiation and fusion indexes representing the propor-
tion of nuclei that were localized within MyHC-positive
myotubes and the formation of multinucleated myotubes,
respectively. Fluorescent images of random fields were
captured with 20× magnification. For each experimental
condition, total number of nuclei and number of nuclei
incorporated into the myotubes were counted. The differ-
entiation index was calculated as the percentage of MHC-
positive cells above total and fusion index was determined
by the percentage of nuclei incorporated into myotubes
(defined as containing at least two nuclei) relative to the
total number of nuclei.
Measurement of mRNA levels by quantitative RT-PCR
RNA was extracted using the TRI reagent (Sigma) and
subjected to DNase digestion (Thermo Fisher Scientific).
Real-time quantitative PCR was conducted using
One-step SYBR GreenER (Thermo Fisher Scientific) in a
7500 Real-time PCR System (Applied Biosystems). Spe-
cific primers were as follows: Fw Ar (5′-TACCAGCT-
CACCAAGCTCCT-3′); Rv AR (5′-GATGGGCTTGA
CTTTCCCAG-3′); Fw Cyp19 (5′-AACCCCATGCAGTA-
TAATGTCAC-3′); Rv Cyp19 (5′-AGGACCTGGTATT-
GAAGACGAG-3′); Fw Cyclophilin A (5′-GTCAACCCC
ACCGTGTTCTT-3′); Rv Cyclophilin A (5′-CTGCTGT
CTTTGGGACCTTGT-3′). Each analysis was performed in
triplicate sessions. Relative expression levels were calcu-
lated using the comparative cycle threshold (ΔΔCt) method
using Cyclophilin A as internal control.
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ELISA assay
After 24 and 72 h of differentiation in the presence or absence
of TAD, media were removed and centrifuged at 500g for 10
min at 4 °C, and supernatants stored at −80 °C until used for
assays. T was measured by sensitive ELISA kit (Enzo Life
Sciences, Inc., Plymouth Meeting, PA, USA) assay. Data
from ELISA assay in the supernatants were normalized for
number of viable cells at the end of each experiment and
expressed in pg/ml. The sensitivity of T kit is 2.6 pg/ml with a
range of detection between 3.9 and 1000 pg/ml.
Statistical analysis
For the clinical study, results are reported as mean± standard
error when normally distributed, and as median (quartiles)
when non-parametric. Data were analyzed using t-tests for
single comparisons, analysis of covariance for comparisons at
specific time points, using baseline score as a covariate.
Multiple stepwise regression analysis was performed to
determine associations between serum endothelial function, E
and insulin concentration after adjusting for potential con-
founders such as age, cigarette smoking, and drug/supple-
mental facts assumption. A p-value< 0.05 was considered
statistically significant. Statistical analysis was performed
using the computer statistical package SPSS 11.0 (SPSS Inc.,
Chicago, IL, USA).
For the in vitro study, all results represent the means ±
SD of at least three independent experiments, and p-values
were calculated using the unpaired t-test.
Results
TAD improves body composition in vivo
After 2 months of both TAD treatments, no significant
changes in total BW or overall FFM/FM were found
(Table 1). Interestingly, 2 months OAD-TAD induced an
increase in FFM (expressed as percentages) both at the
trunk (Fig. 1a; p< 0.01) and android sections (Fig. 1b; p<
0.001) that was lost after 2 months withdrawal, whereas a
similar trend in appendicular FFM was also found (data not
shown). Accordingly, OAD-TAD produced a trend to
reduction in WC (−2.5 cm, Table 1), with significant
reduction of abdominal FM (%) only at the android section
that returned to baseline after 2 months from withdrawal
(Fig. 1c; p< 0.01). IIEF-5 questionnaire also showed a
significant improvement for both treatment groups (Table 1;
p< 0.01), while IPPS scores improved significantly in
OAD-TAD only (p< 0.01). OAD-TAD induced a sig-
nificant drop in E levels (p< 0.001) while no modifications
in circulating TT levels were found, determining significant
reduction of T/E ratio (Table 1; p< 0.01) that returned to
baseline after withdrawal.
Endothelial function (T/Bo) showed significant
improvement after 2 months OAD-TAD (Fig. 2a; p< 0.01)
that returned at baseline after withdrawal. Improvements in
endothelial function showed a direct correlation with insulin
(Fig. 2b; p< 0.01, r: 0.3641) and an inverse correlation with
E serum levels (Fig. 2c; p< 0.01, r: 0.3655), respectively.
No differences in body composition, endothelial function,
Table 1 Clinical characteristics at baseline of the ITT population, after 2-months treatment with daily TAD 5mg and on-demand TAD 20mg, and
after 2-months from withdrawal
OAD–TAD (n= 23) OD–TAD (n= 20)










Weight (Kg) 77.8± 16.8 81.0± 14.9 77.1± 15.5 ns 75.4± 13.9 76.3± 12.6 77.1 ± 13.1 ns
BMI 25.5± 0.9 25.9± 1.0 25.4± 1.1 ns 26.2± 0.8 26.1± 1.1 26.4 ± 1.0 ns
Waist (cm) 97.5± 3.3 95.0± 2.1 97.2± 3.1 ns 98.8± 4.4 99.8± 3.1 99.3 ± 3.9 ns
Lean total (%) 76.2± 4.1 76.5± 4.3 76.3± 3.2 ns 76.1± 4.3 76.2± 4.1 76.0 ± 3.9 ns
Fat total (%) 21.6± 3.7 21.1± 3.6 21.3± 2.8 ns 21.7± 3.1 21.6± 3.4 21.8 ± 3.3 ns
Total T (ng/mL) 5.76± 1.5 5.46± 1.71 5.65± 1.45 ns 5.13± 1.1 4.92 ± 1.87 5.45 ± 1.63 ns
E (pg/mL) 35.2± 9.22 20.75± 4.09** 34.1± 8.32 ** 0.001 38.23± 6.76 32.56± 8.34 39.6 ± 5.98 ns
Total T/E 0.175± 0.07 0.30± 0.1* 0.180± 0.09 *0.01 0.156± 0.09 0.169± 0.8 0.146± 0.09 ns
SHBG (nmol/L) 39.4± 3.1 40.1± 2.8 38.6± 2.9 ns 41.3± 3.8 43.2± 4.7 39.8 ± 3.7 ns
Insulin (mIU/l) 5.9± 0.5 9.1± 0.3* 6.1± 0.4 *0.01 5.4± 0.3 5.9± 0.7 5.3± 0.5 ns
IIEF 5 19± 1.5 24± 0.5* 22± 1.5 *0.01 18± 1.0 25± 1.5* 20± 1.5 *0.01
IPSS 7.5± 0.5 3.1± 0.3* 7.3± 0.4 *0.01 7.3± 0.6 7.9± 0.5 8.3± 0.4 ns
BMI body mass index (kg/m2), E 17β-Estradiol, SHBG Sex Hormone Binding Globulin, IIEF5 International Index of Erectile Function-5 items,
IPSS International Prostate Symptoms Score
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and T/E ratios were found after OD-TAD treatment. Side
effects were those commonly reported with TAD adminis-
tration (headache and myalgia) did not differ between the
two groups and did not determine drug discontinuation
(data not shown).
TAD modulates myogenic differentiation in C2C12
skeletal muscle cells in vitro
For in vitro experiments, TAD concentrations were chosen
(10−7 to 10−6 M) based on previous studies [8, 9, 19],
indicating these concentrations as likely equivalent to the
doses used for in vivo treatment. To evaluate potential
effect of TAD on initiation of differentiation program, cells
were treated with increasing concentrations of TAD and key
myogenic differentiation markers, such as MyoD, myo-
genin, and MyHC, were analyzed after 24 and 72 h expo-
sure by western blot analysis.
TAD (10−7 to 10−6 M) induced a 3.3± 0.7-fold and a 3.9
± 0.9-fold increase in MyoD protein expression after 24 h
exposure as compared with untreated cells, while TAD
(10−6 M) induced a myogenin protein expression increase of
2.8± 0.4-fold and 1.4± 0.02-fold vs. control cells after 24
and 72 h, respectively. The same concentrations of TAD
(10−7 to 10−6 M) induced 1.4± 0.07-fold and 1.6± 0.2-fold
increase in MyHC protein expression, respectively, after
24 h (Fig. 3a, b).
Fusion index for myotubes formation in the differ-
entiated cells increased after 72 h of about 30% from the
onset of differentiation process upon 10−6 M TAD exposure
as compared with untreated cells (Fig. 3d, e). Preliminary
experiments, performed to demonstrate lack of cytotoxicity
effects and to assess cell viability, by trypan blue exclusion
assay and MTS assay, did not demonstrate differences
between treated and untreated cells (data not shown).
TAD increases AR expression
As depicted in Fig. 4a, RT-qPCR analysis revealed a 1.3±
0.08-fold increase of AR mRNA content in cells treated
with 10−6 M TAD for 12 h (p< 0.05) reaching a 1.5± 0.08-
fold increase after 24 h (p< 0.05) as compared with
untreated cells. Increase was lost after 48 h. Western blot
analysis further supported an increase in AR protein
Fig. 1 Differences after
daily TAD treatment in lean and
FM (gr=grams) from baseline.
Daily TAD 5mg produced
a) significant variation in lean
trunk fat (p< 0.01, 2–months vs.
baseline) that returned at
baseline levels after 2 months
from withdrawal; b) significant
variation android trunk lean
mass (gr) (p< 0.001—2-months
vs. baseline) that returned at
baseline levels after 2 months
from withdrawal. Also,
c) a significant variation in
android trunk FM (gr) (p< 0.01
—2-months vs. baseline) that
returned at baseline value after
2 months from withdrawal was
found
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expression (2.0 ± 0.3-fold) in TAD-treated vs. untreated
cells (p< 0.05) (Fig. 4b). Since a rapid regulation of Cyp19
(ARO) mRNA and protein level was previously observed in
TAD-treated human adypocytes, eight potential modula-
tions were evaluated in muscle cells as well. TAD (10−6 M)
induced a 1.4± 0.07-fold increase of Cyp19 mRNA
expression in the cells 12 h after the differentiation induc-
tion (p< 0.05, data not shown), but the effect was blunted
after 24 h. Moreover, western blot analysis showed a 2.5±
0.7-fold increase of Cyp19 protein levels in TAD-treated
cells at 24 h and a return to control level after 48 h (p<
0.05, data not shown).
In accordance with an upregulation of AR expression, a
relevant increase of T concentrations in the supernatant of
10−6 M TAD-treated cells (2.3 ± 0.5-fold compared with
untreated cells, p< 0.05) was found after 24-h treatment,
that was also blunted after 48 h (data not shown). Unfor-
tunately, it was not possible to detect E levels in C2C12
supernatant cells, since values resulted too low as with
commercial high sensitive ELISA kits available (data not
shown).
Since T regulates PDE5 expression and responsiveness to
TAD in human corpus cavernosum, [20] the expression
level of this enzyme was evaluated during C2C12 muscle
cells differentiation with or without TAD. PDE5a mRNA
level increased after 48-h differentiation into myotubes (1.5
± 0.02 vs. undifferentiated cells, data not shown), con-
firming previous studies in human primary skeletal muscle
cells [21]. By contrast, TAD did not affect PDE5a mRNA
expression in the same experimental conditions.
Discussion
This is the first demonstration that shows that short-term
daily TAD administration improves body composition in
men by concomitant increases in FFM and decreases in FM
with a tendency to decrease in WC. These latter results are
in line with studies in vivo in the rabbit model, showing
beneficial effects of TAD on visceral adipose tissue pre-
adipocyte phenotype and amelioration of MetS features,
that were corroborated by further demonstrating an in vitro
upregulation of expression of genes related to brown/beige
commitment, and mitochondrial fusion. [10] In our young
healthy subject affected by mild ED/LUTS, we found
interesting modifications in hormonal milieu, i.e., higher T/
E ratio and increased insulin production, along with mul-
tivariate analysis showing significant association with
insulin, E plasma levels, and endothelial function. This
Fig. 2 Treatment with daily
TAD treatment produced a
significant improvement of
a) endothelial function (T/Bo,
p< 0.05; 2-months vs. baseline)
that returned at baseline levels
after 2 months from withdrawal.
Endothelial function (T/Bo)
directly correlated with
b) insulin (p< 0.01; r= 0.3641)
and inversely correlated with
c) E serum levels (p< 0.01;
r= 0.3655), respectively
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result was relevant, since obtained with no changes either in
lifestyle and/or physical activity during the study.
The efficacy of long-term treatment with PDE5i awaits
demonstration in human metabolic diseases, i.e., T2D and
MetS. Preclinical data suggest that cGMP signaling affects
energy balance, insulin resistance, and glucose metabolism,
and might be related to vasodilation (resulting in increased
perfusion and substrate delivery to metabolically active
skeletal muscle)—through direct effects on peripheral glu-
cose handling [22, 23]. Chronic treatment with sildenafil in
a mouse model of diet-induced insulin resistance caused a
significant improvement in energy expenditure and insulin
sensitivity [24]. In animal models, chronic sildenafil
improved cardiac performance [25] and reduced interstitial
cardiac fibrosis [26]. In men with T2D, Fiore et al.
demonstrated that daily sildenafil improved WC and
epicardial fat, and demonstrated that this occurred by reg-
ulation of miR22 release and SIRT1.[11] Also Ramirez
et al. demonstrated that chronic sildenafil administration in
overweight men with pre-diabetes enhanced insulin sensi-
tivity and improved markers of endothelial function [27].
Hill et al. demonstrated that TAD administration (10 mg on
alternate days for 3 weeks in men with MetS) was asso-
ciated with improved pancreatic β-cell function, as assessed
by oral glucose tolerance testing, when compared with
placebo [28]. Accordingly, acute TAD administration had
beneficial effects on peripheral microcirculation and glucose
uptake also in insulin-resistant diabetic women [29]. Recent
discoveries support the evidence that endothelial dysfunc-
tion may be the cause of insulin resistance and T2D, due to a
decrease in NO levels, reducing cGMP production, and
impairing muscle glucose uptake [30]. Due to TAD action
Fig. 3 TAD effect on muscle cells differentiation and myotube for-
mation in vitro. C2C12 muscle cells were induced to differentiate in
the presence or absence of different concentrations of TAD (10−7 to
10−6 M). Cell lysates were collected after 24 and 72 h of differentiation
and analyzed by Western blotting. a) Representative Western blot
analysis of MyoD, Myogenin and MyHC protein contents b) Histo-
grams represent mean values of MyoD, Myogenyn and MyHC protein
levels ratio normalized over the GAPDH protein level c) Repre-
sentative image of immunofluorescence staining for MyHC after 72 h
of differentiation. Differentiation d) and fusion indexes e) in cells
treated with or without TAD (10−7 to 10−6 M) were calculated as
reported in materials and methods. Results are presented as mean± SD
(n= 3) from three different experiments. Scale bars= 75 μm; ** p ≤
0.01 and * p ≤ 0.05 vs. untreated cells
Endocrine
on insulin and on glucose metabolism in C2C12 cells, [12]
we further investigated possible acceleration of myogenic
differentiation and an increased AR expression in these
cells. The underlying mechanisms by which T/AR signal-
ling regulates metabolic homeostasis in men are complex,
but evidences derived from various AR knockout mouse
models reveal tissue-specific AR signalling that are
involved in the regulation of metabolism [31]. MyoD and
Myogenin regulate the program of skeletal muscle differ-
entiation: in fact, MyoD plays a crucial role in cells com-
mitment to myogenesis program, while myogenin takes part
in the execution of differentiation program [32]. Indeed, we
found a relevant increase of MyoD accumulation after 24 h
of differentiation. It is known that the muscle-regulatory
transcription factor myogenin appears at a later stage leading
to the commitment of differentiation; [33] interestingly,
TAD-treated cells showed an earlier transcription after 24 h
differentiation when compared with the control ones. MyHC
is part of sarcomeric structure of skeletal muscle and occurs
at the end terminal differentiation into functional myotube
[34]. When the cells were treated with TAD, it was observed
an increase of MyHC expression and myotube fusion index
after 72 h from the onset of differentiation. Since clinical
study showed a clear increase in T/E ratio, [35] a more
favorable androgen milieu is hypothesized in vivo that could
activate AR transduction cascade involved in myogenesis.
This pathway may determine a more selective modulation of
AR and acceleration of the differentiation process in skeletal
muscle cells in vitro, [36] suggesting that this event might be
one of the potential mechanism leading to the improvement
of FFM in our clinical study. The possible relationship
between TAD use, AR pathway physiology, muscle cell
differentiation, and hormones adaptation [37] should be
evaluated in healthy athletes abusing with TAD [38] and
androgenic anabolic steroids.
We recognize several limitations of this study. Despite
any changes in lifestyle or caloric intake were permitted to
patients throughout the entire study duration, the lack of a
placebo arm limits the interpretation of our results. It is
important to recognize that DEXA may not accurately
assess body composition when compared with CT-scans,
but mostly in markedly obese subjects. No evaluation of
inflammation markers was provided. In addition, although
in vitro results suggest a possible role of AR signalling
pathway in mediating TAD effects on skeletal muscle cell
differentiation, further studies are warranted to elucidate the
translational mechanisms involved in TAD effects on ske-
letal muscle myogenesis.
In conclusion, we demonstrated for the first time that
TAD exerts modulatory effects on body composition
in vivo in metabolically healthy men and on skeletal muscle
cell differentiation in vitro. As expected, mild ED symp-
toms improved in both groups, while LUTS amelioration
was evident during daily administration only. The hormonal
and microcirculation variations induced by TAD in clinical
subjects accompanied by in vitro muscle cell line differ-
entiation suggest a translational action of PDE5i on skeletal
muscle possibly mediated via AR.
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